{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-047276","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.899413+00:00","generated_at":"2026-05-30T02:10:39.762427+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ginkgo Q3 total rev $89M (+61% YoY) includes $45M deferred release; core $44M (-21%); guides FY $215-235M","bullets":["Total revenue $89M (+61% YoY) incl. $45M non-cash deferred revenue; core rev $44M (-21%).","Cell Engineering ex-deferred $30M (-20% YoY); Biosecurity $14M with 28% gross margin.","Loss from ops $(55)M vs $(286)M; Adj EBITDA $(20)M vs $(84)M.","FY24 guidance raised: Total rev $215-235M, Cell Eng $165-185M, Biosecurity ≥$50M.","Appointed Dr. Sri Kosuri to Board; Dr. Belldegrun resigned. Signed deal with Novo Nordisk; Merck milestone $9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-047276","json":"https://secwatch.observer/filing/0001628280-24-047276.json","markdown":"https://secwatch.observer/filing/0001628280-24-047276.md","text":"https://secwatch.observer/filing/0001628280-24-047276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/0001628280-24-047276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/dna-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:10:39.762427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dbf6db56cc","claim":"Dr. Arie Belldegrun resigned as Director at Ginkgo Bioworks Holdings, Inc..","evidence_excerpt":"On November 7, 2024, Dr. Arie Belldegrun resigned from his position as a director of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/0001628280-24-047276-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ed2e8dac5f","claim":"Dr. Sri Kosuri was appointed as Class B Director at Ginkgo Bioworks Holdings, Inc..","evidence_excerpt":"On November 6, 2024, the Class B directors of the board of directors (the “Board”) of the Company appointed Dr. Sri Kosuri to the Board as a Class B director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/0001628280-24-047276-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class B Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}